Research progress of programmed cell death protein-1 inhibitor combined with chemotherapy in advanced gastric cancer

Abstract

The survival rate and quality of life of patients with advanced gastric cancer are low. Despite the continuous development and improvement of chemotherapy regimens for advanced gastric cancer, the survival rate of patients with advanced gastric cancer is still low. At present, not only are comprehensive treatment methods very limited for advanced gastric cancer, but there is also a lack of posterior treatment methods. Therefore, there is an urgent need for effective treatment plans for advanced gastric cancer. In recent years, with the in-depth research on tumor immunology, immunotherapy has become a focus of attention. Programmed cell death protein-1 (PD-1) inhibitor, as an immunosuppressive drug, combined with chemotherapy, can not only maximize the clinical activity of immunosuppressive drug, but also establish a lasting immune response. At present, the combination of PD-1 inhibitors and platinum chemotherapy has shown high clinical application value in clinical research of advanced gastric cancer. This article reviews the research progress of PD-1 inhibitors combined with chemotherapy for advanced gastric cancer, aiming to provide a basis for clinical application.

Keywords

• advanced gastric cancer
• programmed cell death protein-1 inhibitor
• immunotherapy
• chemotherapy
• sintilimab
• pembrolizumab
• nivolumab
• camrelizumab
• tislelizumab